Highlights – 3rd Quarter 2013
- Accelerated implementation of efficiency measures
- Solid organic sales growth of ~ 5%
- Significant increase in EBITDA pre one-time items powered by structural improvements from the “Fit for 2018” transformation program and despite negative currency impacts
- Merck Serono: Strong organic sales performance of 5.2% driven by Emerging Markets and Japan
- Consumer Health: Turnaround on track underlined by strong earnings in Q3 2013
- Performance Materials: Solid development despite first signs of inventory destocking in the display industry
- Merck Millipore: Excellent business performance thanks to its balanced portfolio
- Earnings per share pre one-time items up 15.7% to € 2.29
- Significant net financial debt reduction to € 0.5 billion at the end of the quarter
- Guidance raised for FY 2013: EBITDA pre one-time items ~ € 3.2 billion – € 3.25 billion
| XLS |
|
Merck Group | Key figures | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ million |
Q3 – 2013 |
Q3 – 2012 |
Change |
Jan.–Sept. |
Jan.–Sept. |
Change |
|
Total revenues |
2,751.8 |
2,841.0 |
–3.1% |
8,353.4 |
8,338.1 |
0.2% |
|
Sales |
2,659.5 |
2,721.7 |
–2.3% |
8,063.8 |
8,028.7 |
0.4% |
|
Operating result (EBIT) |
481.8 |
318.1 |
51.4% |
1,346.6 |
651.9 |
106.6% |
|
Margin (% of sales) |
18.1% |
11.7% |
|
16.7% |
8.1% |
|
|
EBITDA |
796.4 |
661.0 |
20.5% |
2,343.4 |
1,689.4 |
38.7% |
|
Margin (% of sales) |
29.9% |
24.3% |
|
29.1% |
21.0% |
|
|
EBITDA pre one-time items |
830.7 |
754.2 |
10.1% |
2,458.1 |
2,175.1 |
13.0% |
|
Margin (% of sales) |
31.2% |
27.7% |
|
30.5% |
27.1% |
|
|
EPS pre one-time items (€) |
2.29 |
1.98 |
15.7% |
6.66 |
5.56 |
19.8% |
|
Free cash flow |
743.8 |
814.8 |
–8.7% |
1,732.0 |
1,860.2 |
–6.9% |
search hit 07
